Fintech PR
QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
MELBOURNE, Australia and DRESDEN, Germany, March 18, 2024 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement to commercially partner the QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH (ABX-CRO), a full-service contract research organisation (CRO) based in Dresden, and its development partner, Stockholm-based Quantinm AB.
QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals. Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens. Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains.
QDOSE® supports dosimetry calculations using planar imaging, tomographic imaging, single/multi time point imaging and hybrid combinations. QDOSE® incorporates additional tools for attenuation and background correction. The QDOSE® platform will be integrated with Telix’s artificial intelligence (AI) products as an accessible tool for clinicians and third-party commercial drug developers. QDOSE® has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is Conformité Européenne (CE) marked for clinical use within the European Union (EU).
Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “In nuclear medicine, dosimetry analysis is used to calculate the absorbed dose of radiation received by different parts of the body. Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis. QDOSE® has an excellent performance track record and we are committed to positioning QDOSE® as a new industry standard in dosimetry analysis.”
The arms’ length up-front transaction consideration is non-material. Telix will pay undisclosed product royalties and fees on product sales.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA,[1] by the Australian Therapeutic Goods Administration (TGA),[2] and by Health Canada.[3] Telix’s miniaturised surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, has attained a marketing authorisation in the U.S., having been registered with the FDA and has attained a CE Mark for use in the European Economic Area for the intra-operative detection of sentinel lymph nodes. With the exception of Illuccix® and SENSEI® as noted above, no Telix product has received a marketing authorisation in any jurisdiction.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]
Legal Notices
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.
This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Illuccix® and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
|
[1] Telix ASX disclosure 20 December 2021. |
|
[2] Telix ASX disclosure 2 November 2021. |
|
[3] Telix ASX disclosure 14 October 2022. |
Logo – https://mma.prnewswire.com/media/1920208/4598441/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/qdose-platform-partnership-for-personalised-dosimetry-in-radiopharmaceutical-therapy-302092075.html
WASHINGTON, Dec. 19, 2024 /PRNewswire/ — The global law firm Jones Day announces that the 37 lawyers listed below will be admitted to the Firm’s partnership effective January 1, 2025.
“This class of new partners once again reflects Jones Day’s ability to provide our valued clients the guidance and legal solutions for their most complex business challenges across the globe,” said Gregory M. Shumaker, Managing Partner of Jones Day.
The full announcement is also available on Jones Day’s website. The list follows:
- Rebecca Wernicke Anthony, Business & Tort Litigation, Dallas
- Matthew Barrett, Corporate, London
- Joseph C. Barry, Financial Markets, Cleveland
- Irina K. Bleustein, Securities Litigation & SEC Enforcement, Washington
- Mathis Bredimus, Corporate, London
- Kelsey S. Bryan, Business & Tort Litigation, Los Angeles
- Emily W. Cai, Corporate, New York
- Diana L. Calla, Business & Tort Litigation, San Francisco
- Andrew J. Clopton, Issues & Appeals, Detroit
- Arturo de la Parra, Financial Markets, Mexico City
- Adrien Descoutures, Corporate, Paris
- Preslava Dilkova, Government Regulation, Brussels
- Amanda L. Dollinger, Financial Markets, New York
- Anna A. Dwyer, Real Estate, Chicago
- Justin P. Farra, Corporate, Columbus
- Matthew J. Gherlein, Financial Markets, Cleveland
- Fabio Maria Guidi, Financial Markets, Milan
- Ryan Harmanis, Business & Tort Litigation, Columbus
- Jared P. Hasson, Corporate, Cleveland
- Andrew D. Iammarino, Financial Markets, Cleveland
- Kurt A. Johnson, Detroit, Issues & Appeals
- Andrew J. Junker, Business & Tort Litigation, Dallas
- Thomas S. Koglman, Intellectual Property, Cleveland
- Laura E. Koman, Health Care & Life Sciences, Washington
- Marta Lahuerta Escolano, Government Regulation, Paris
- Justin D. Martin, Labor & Employment, Miami
- Alexander V. Maugeri, Government Regulation, New York
- Justin W. McKithen, Financial Markets, Atlanta
- Karl S. Moussalli, Global Disputes, London
- Victoria Cuneo Powell, Business & Tort Litigation, Atlanta
- Gabrielle E. Pritsker, Business & Tort Litigation, Washington
- Kaitlinn P. Sliter, Corporate, Chicago
- Bijan Tavakoli, Government Regulation, Frankfurt
- Jessica Tierney, Health Care & Life Sciences, Washington
- Collin L. Waring, Real Estate, Dallas
- Ann-Marie Woods, Labor & Employment, Chicago
- Jason Z. Zhou, Business & Tort Litigation, Chicago
Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents. The Firm is distinguished by: a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
Photo – https://mma.prnewswire.com/media/2584725/Jones_Day_New_Partners.jpg
View original content:https://www.prnewswire.co.uk/news-releases/jones-day-names-37-new-partners-302335622.html
- Homeowners are wasting £100s on professional household repairs
- Going DIY on chair and fence fixes could save Brits up to £400
- Evolution Power Tools reveals where to pick up FREE wood & cut costs down
SHEFFIELD, England, Dec. 18, 2024 /PRNewswire/ — Nobody likes being faced with worn, damaged or faulty objects around the house – but before Brits rush out and spend £100s on replacements or repairs, it’s worth considering the DIY approach.
DIY enthusiasts from Evolution Power Tools reveal how common household issues can easily be fixed – without needing to spend much on multiple tools and materials in the process.
“With just weeks until Christmas, we’d much rather spend our money on gifts for loved ones instead of forking out for furniture repairs.
“We always encourage homeowners to repair and not replace. What’s more, repairing furniture yourself can be a rewarding experience and doesn’t have to cost as much as you might think.
“For example, when your chair has wobbly legs, it’s tempting to buy a replacement – or pay for professional repairs.
“It might sound cost-savvy to get a repair, but getting the professionals in can cost more than you’d think.
“The average professional chair leg repair can cost up to £300.
“But by using a mitre saw, timber, screws, glue and sandpaper, you can get the job done yourself for a fraction of the price.
“If you don’t have a saw of your own, ask friends and family if you can borrow one.
“Plus, did you know you can pick up timber for free by browsing Facebook Marketplace or asking local construction sites if they have any scraps going?
“Then you can pick up screws, wood glue and sandpaper from B&Q for under £20 – saving you over £280!
“Similarly, a broken fence can feel like a nightmare – but you don’t have to call in a professional and pay in the region of £150.
“One solution is getting hold of some pallet wood – and this doesn’t have to cost a penny.
“Depending on where you live, your local IKEA may be getting rid of excess supplies – so you may find wood available to pick up for free.
“Then all you need is a hand saw or circular saw – which you may have, or could borrow – plus a hammer and nails, measuring tape and a level.
“Most people will have these supplies at home – which means you could save the best part of £150!”
Top 5 tips for picking up free wood
- Ask local businesses. If you see a supermarket worker emptying a pallet of products, ask if the wood is being thrown away. If so, you may be able to grab it for free.
- Go to your local recycling facility. Many people will dispose of excess materials, including wood, by taking it to the tip. All you have to do is ask the staff if you can take it.
- Visit IKEA. Certain branches will make their surplus materials available for free. The scheme isn’t always running, but it’s worth keeping an eye out!
- Check online marketplaces. Sites like Facebook Marketplace have a surprising amount of supplies going for free, as people just want to get rid of it.
- Construction sites. These places may be glad to have someone pick up excess materials, as it saves them having to dispose of it.
“If you’ve got multiple furniture repairs to carry out, it can be cost-efficient to buy a tool with a multi-material cutting blade.
“Featuring a Japanese Tungsten Carbide Teeth blade, these versatile tools will simplify your toolkit, while allowing you to carry out DIY projects with ease
“Our multi-material cutting tools provide clean and accurate cuts through a variety of materials, including wood, metal, plastics and even wood with nails,
“Gone are the days of homeowners needing to constantly swap blades or purchase specialist equipment. Now, you can rely on one tool to do it all, making DIY much more efficient and enjoyable.
“By investing in versatile tools or borrowing existing equipment, you can avoid unnecessary costs and breathe new life into your household items at a fraction of the price.”
About the company: Evolution Power Tools is a global leader in multi-material technology, with over 30 years in the industrial power tool market.
They are part of a growing movement which encourages homeowners to feel empowered when carrying out DIY, and as such, design tools that help to tackle a variety of tasks without the need for expertise.
Evolution Power Tools never compromise on performance, and their patented technology is no exception, it is reliable with a 3 guarantee, accurate, ergonomic, and powerful for the most precise cuts on a multitude of materials.
- Pricing information accurate at the time of submission
- Cost of smaller supplies for DIY fixes have been sourced from B&Q
- We would appreciate a link to the Evolution Power Tools website within the copy, if you decide to publish the article
- Evolution Power Tools is based in the steel city of Sheffield and has a worldwide reputation for premium and professional tools.
- Their tools have been featured on TV shows including Top Gear, DIY SOS, and Grand Designs
Photo: https://mma.prnewswire.com/media/2583046/Evolution_Power_Tools.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/evolution-power-tools-reveals-diy-hacks-to-save-400-on-everyday-household-repairs-302335209.html
– Approval positions the FinTech as a leader in crypto-asset innovation and compliance in the EU, allowing it to expand its transformative digital-native payments platform and enter new markets –
AMSTERDAM, Dec. 18, 2024 /PRNewswire/ — ZBD, the innovative payments company at the forefront of digital economies, today announced it has become the first company to receive approval for the new European Union (EU) crypto-asset service provider license under MiCAR (Markets in Crypto-Assets Regulation). This landmark achievement represents a major milestone both in crypto-asset regulation in the EU and in ZBD’s journey to build a digital-native payments platform on top of the Bitcoin Lightning Network.
The Dutch Authority for the Financial Markets (AFM) has approved ZBD’s license application under MiCAR, and will issue its license when MiCAR takes effect on 30th December 2024. MiCAR is a new regulatory framework that all crypto-asset service providers in the EU must comply with. Securing a license under MiCAR allows ZBD to expand its capabilities by offering a wide range of services including crypto-asset custody, administration, transfers, and—crucially—fiat-to-crypto and crypto-to-fiat exchange. It also demonstrates a strict adherence to the highest standards of compliance and consumer protection for ZBD’s EU users.
While many companies, including the world’s largest exchanges, are struggling to navigate MiCAR’s stringent requirements, ZBD’s comprehensive and proactive approach to compliance has positioned it to lead the way in crypto-asset innovation and better serve customers across the EU. MiCAR therefore presents a unique opportunity for ZBD as it begins its expansion into the EU market after establishing a strong presence in the US.
“Being the first to have received MiCAR license approval is a major leap forward for us,” says Marca Wosoba, COO of ZBD. “We’ve built a culture where compliance is at the forefront of what we do, and we see it as an enabler for new functionality, not a blocker. MiCAR gave us an opportunity to obtain licensing across all of the EU and facilitate our expansion in the region.”
This milestone aligns with ZBD’s broader vision to build digital-native payments infrastructure for the gaming and entertainment industries. Unlike traditional FinTech companies, which typically start with a fiat-first model and then add on crypto functionality, ZBD flips the script—building on Bitcoin’s Lightning Network to enable fast, low-cost, and globally scalable payments. This flexibility allows the company to find product market-fit in the gaming space, serving use cases that are simply not possible with traditional finance, such as instant reward payouts with no minimums – gamers can earn money playing games and cash out as soon as they’ve earned even a fraction of a cent.
“Having already built a stable revenue-generating business gives us a great entry point to expand what we do and move towards our vision of building a payments company that can instantly move money in any currency,” added Wosoba. “It’s not about being a crypto or Bitcoin business, it’s about being a digital-native payments business that happens to use Bitcoin on the Lightning Network as a core technology in our internal tech stack.”
ZBD took a proactive and strategic approach in anticipation of the new regulation, submitting its MiCAR registration application at the earliest opportunity. Its strong, collaborative relationship with The Dutch Authority for the Financial Markets (AFM), which was the first in the EU to accept and process applications, was also instrumental in achieving this significant milestone.
The license under MiCAR primes ZBD to launch more complex payment products built around Bitcoin, as well as grow rapidly in the EU in 2025. It also brings ZBD one step closer to achieving its ambitious vision as a transformative digital-native payments company. Following its ethos of building crypto-first and then adding complementary fiat functionality, the company is also in the final stages of receiving an Electronic Money Institution (EMI) license, which will complement the range of services ZBD can offer under MiCAR, by also granting it license to perform a wide range of fiat payments services in the EU.
About ZBD
ZBD is a leader in payments innovation, pushing the boundaries of how we move money across the internet. Within gaming, ZBD has made a name for itself by powering instant real-money rewards for partners ranging from Square Enix to 1047 Games. Beyond gaming, ZBD enables unique payments-based use cases across interactive entertainment and adjacent industries. Whether it’s streaming money alongside audio in podcasting apps like Fountain, or implementing instant revenue sharing for each ad impression for adtech innovators like Slice and AdInMo, ZBD makes money move online as seamlessly as information.
To learn more, visit https://zbd.gg/
Photo: https://mma.prnewswire.com/media/2584112/ZBD.jpg
Logo: https://mma.prnewswire.com/media/2583320/ZBD_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/zbd-becomes-first-to-receive-eu-micar-license-approval-302335116.html
-
Fintech6 days agoFintech Pulse: Your Daily Industry Brief (Nuvei, Google, Upvest, Gen Digital, MoneyLion)
-
Fintech PR6 days agoCathay Financial Holdings Calls for Climate Finance Mobilization to Drive the Climate Industrial Revolution
-
Fintech2 days agoFintech Pulse: Your Daily Industry Brief (Synapse, Shenzhen Institute, Visa, AutomatIQ, MeridianLink)
-
Fintech PR6 days agoA New Era of $WUSD — Revolutionizing Stablecoins with Unmatched Security, Stability and Next-Gen Innovation
-
Fintech PR5 days agoLanistar launches new gaming sites in Brazil as secures right to operate pending final approval on its licence
-
Fintech PR5 days agoHealthcare Revenue Cycle Management (RCM) Market Surges to USD 658.7 Billion by 2030, Propelled by 24% CAGR – Verified Market Reports®
-
Fintech1 day agoFintech Pulse: Your Daily Industry Brief (Revolut, Bestow, Advyzon, Tyme Group, Nubank)
-
Fintech PR6 days agoInternational Communication Forum: Pathways To A Sustainable Future